Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-45

Must confess I sold 20% of my holdings on the uptick. Buying back here. The mkt just doesn't like the twice a week results not being as powerful vs previous data which was very strong. Its a Phase II trial people. They are statistically testing at poking at different delivery times etc, to prepare themselves for a phase III trial from the best approached to get a powered statistical return in the primary when they go for the Phase III.

Unfortunately, as history has shown, you can have the best promising drugs/treatments in the world, but unless your statistical proof is very robust, you aint going anywhere in the "nothing short of a resolute RCT result" will do regulatory environment.